(Circulation. 2001;104:2424.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Department of Kinesiology and Applied Physiology, University of Colorado at Boulder (P.P.J., L.F.S., G.A.K., D.R.S.); the Department of Medicine, University of Colorado Health Sciences Center, Denver (L.F.S., R.A.Q., D.R.S.); the Clinical Research Center, Franz Volhard Clinic at the Max Delbrück Center, Medical Faculty of the Charité, Humboldt University, Berlin, Germany (J.J.); and the Autonomic Dysfunction Center, Vanderbilt University, Nashville, Tenn (J.R.S.).
Correspondence to Pamela Parker Jones, PhD, Department of Kinesiology and Applied Physiology, UCB 354, University of Colorado, Boulder, CO 80309. E-mail pamela{at}spot.colorado.edu
| Abstract |
|---|
|
|
|---|
Methods and Results A total of 23 young (aged 24±1 years; systolic/diastolic BP, 126±2/66±1 mm Hg) and 16 older (aged 65±1 years; systolic/diastolic BP, 125±3/62±2 mm Hg) healthy men were studied before and during ganglionic blockade (intravenous trimethaphan). The reduction in mean BP (radial artery catheter) with trimethaphan was almost twice as great in the older men (-33±2 versus -19±2 mm Hg; -40% versus -22% of baseline; P<0.01) due to a lack of increase in heart rate (3±2 versus 25±2 bpm; P<0.001) and cardiac output (-0.42±0.19 versus 1.01±0.26 L/min; P<0.001); the decreases in systemic vascular resistance were not different. The absence of tachycardia in the older men was associated with reduced baseline heart rate variability (HRV, P<0.05); the change in heart rate with trimethaphan correlated with the standard deviation of the R-R intervals (HRVSD R-R interval; r=0.57, P<0.001). Among individual subjects (pooled groups), the reductions in mean BP with trimethaphan were most strongly related to measures of sympathetic activity (r=0.58 to 0.67, P<0.005), change in mean BP with intravenous phenylephrine (r=0.57, P<0.001), and HRVSD R-R interval (r=-0.40, P<0.01).
Conclusions ANS support of BP is altered with age in healthy men due to less cardiac vagal inhibition of heart rate and cardiac output. Basal sympathetic activity and
-adrenergic vascular sensitivity are also key physiological correlates of ANS support of BP in healthy men.
Key Words: nervous system, autonomic cardiac output heart rate
| Introduction |
|---|
|
|
|---|
Several changes in the ANS occur with healthy aging in adult humans. 2 Cardiac vagal modulation of heart rate is decreased. 36 Plasma norepinephrine concentrations and total spillover are increased, 7,8 and SNS activity is elevated to the heart, gut, and skeletal muscle, but not obviously to the kidney. 2,911 The hemodynamic impact of the increases in SNS tone may, however, be offset by a decrease in adrenergic sensitivity with age. 1214
The net effect of these age-related changes in ANS function on the tonic systemic cardiovascular regulation of BP is unknown. We hypothesized that ANS support of BP would be altered with healthy human aging. Thus, the primary experimental aim of this study was to determine the decrease in BP in response to short-term ganglionic blockade 15,16 in young and older healthy adults. A secondary aim was to determine the systemic hemodynamic mechanisms contributing to the hypothesized altered ANS support of BP with age, as well as the modulatory influences of the cardiac vagus, SNS activity, and
-adrenergic vascular sensitivity.
| Methods |
|---|
|
|
|---|
Experimental Procedures
Subjects were admitted to the University of Colorado Adult General Clinical Research Center the evening before pharmacological testing. For the preceding 48 hours, subjects consumed a eucaloric, controlled sodium (150 mEq/d) and potassium (70 mEq/d) diet. All were studied during supine rest beginning at 8:00 AM. Radial artery catheterization (20G, 5-cm catheter; Arrow) was performed under local anesthesia (1% lidocaine) using standard aseptic procedures; the catheter was flushed with heparinized saline (2 U/mL) at 3cc/h. Two intravenous catheters were placed in the contralateral arm for drug infusions.
Measurements
Plasma volume was measured by a modified Evans Blue dye technique (New World Trading), with total blood volume calculated from simultaneous measurements of plasma volume and hematocrit in triplicate. 17,18 During pharmacological testing, BP was continually monitored by a pressure transducer connected to the arterial catheter, and heart rate was monitored by ECG (Hewlett-Packard Merlin Patient Monitoring System). The ECG, BP, and respiratory signals were digitized (CODAS, Dataq Instruments) at 500 Hz.
Heart rate variability (HRV) was determined as described previously by our laboratory.19 Heart rate, mean R-R interval, and the standard deviation of the R-R intervals (HRVSD R-R interval, a time domain measure of HRV) were computed from the beat-to-beat R-R intervals, whereas frequency domain measures of HRV were obtained using power spectral analysis.
Cardiac output was measured as previously described 20,21 using 2D echocardiography (Hewlett-Packard ultrasonography 2500) with a 3.5-Mz phased-array transducer using the parasternal short-axis view. Care was taken to measure the maximal flow velocity of the left ventricular outflow tract parallel to the flow envelope. The velocity envelope was integrated over time (velocity time integral) and corrected for the orifice size (2
r2, with the left ventricular outflow tract as the radius). A total of 3 cardiac cycles were averaged to yield a mean cardiac output. All measurements were made by a certified echotechnician according to the guidelines of the American Association of Echocardiography. Systemic vascular resistance and systemic vascular conductance were calculated as the quotients of mean BP/cardiac output and cardiac output/mean BP, respectively.
Plasma samples were analyzed for both catecholamine 22 and vasopressin 23 concentrations.
Protocol
The protocol was modified from that described in detail previously. 15 After a stable 30-minute baseline, 10-minute resting measurements of heart rate, BP, and cardiac output were obtained. NN-cholinergic receptors were blocked by a continuous intravenous infusion of trimethaphan (Cambridge Laboratories Limited). Infusions started at 2 mg/min and increased by 2 mg/min at 6-minute intervals up to 6 mg/min or until blockade was established by no fluctuations of heart rate and BP with respiration. Complete cardiovascular-autonomic blockade was documented by heart rate changes of <5 bpm with a 25 mm Hg increase in systolic BP resulting from a bolus injection (<1 second) of phenylephrine (25, 50, and/or 100 µg). After a 20-minute washout period, measurements of heart rate, BP, and cardiac output were repeated under ANS blockade. Arterial blood samples were drawn at rest and during ANS blockade, 30 to 40 minutes after the bolus injection of phenylephrine. Differences between baseline and trimethaphan were taken as the measure of ANS support. To determine vascular
-adrenergic responsiveness, while still under ganglionic blockade phenylephrine was infused intravenously in 6-minute steady-state doses (0.02, 0.04, 0.08, 0.16 µg · kg-1 · min-1) until mean BP increased 25 mm Hg above baseline. On completion of all measurements, trimethaphan infusion was stopped, and subjects were monitored until completely recovered.
Muscle Sympathetic Nerve Activity
To confirm the presence of age-associated elevations in tonic peripheral SNS activity, on a separate day we measured muscle sympathetic nerve activity (MSNA) in a subset of 12 older (66±2 years) and 10 young (27±1 years) men from the original groups. Multiunit recordings of MSNA were obtained from the right peroneal nerve at the fibular head using the microneurograpic method, as described previously. 10,24 Subjects were studied in the supine position after a 12-hour fast. Ten-minute resting levels of MSNA were obtained subsequent to a stable 10-minute baseline period.
Statistical Analyses
Group comparisons for baseline characteristics were made using unpaired t tests. Responses to trimethaphan were analyzed using a 2-way ANOVA with repeated measures [age groupxcondition (baseline versus autonomic blockade)]. Relations of interest were determined using univariate correlations. The slope of the increase in mean BP with incremental phenylephrine infusion was used to determine
-adrenergic vascular sensitivity. All data are reported as mean±SE.
| Results |
|---|
|
|
|---|
|
Responses to Ganglionic Blockade
Systolic, diastolic, and mean BP decreased (P<0.001) in response to trimethaphan in both groups; each of the decreases was greater in the older men (P<0.001). Mean BP decreased 33±2 mm Hg (40%) from baseline in the older men compared with only 19±2 mm Hg (22%) in the young men (Figure 1).
|
The greater fall in mean BP in the older men was due to an
10% decrease in cardiac output compared with an
20% increase in the young men (P<0.001); the decreases in systemic vascular resistance (increases in systemic vascular conductance) were not different. Stroke volume decreased similarly in the 2 groups during trimethaphan. Therefore, the decrease in cardiac output in the older men was solely due to a lack of increase in heart rate (3±2 bpm; P=NS versus baseline), whereas the increase in cardiac output in the young controls was mediated by significant tachycardia (25±2 bpm; P<0.001 versus baseline). Baseline HRV was lower in the older men (HRVSD R-Rinterval, 51±9 versus 4±1 ms; P<0.05; high frequency power of HRV, P=0.01; Figure 1). In all subjects, the change in heart rate with trimethaphan was positively related to baseline HRVSD R-R interval (r=0.57, P<0.001; Figure 2) and high frequency power of HRV (r=0.41, P<0.01).
|
Plasma norepinephrine concentration decreased from baseline during trimethaphan in both groups (P<0.001); the decrease was greater in the older men (-1.29±0.12 versus -0.62±0.06 nmol/L; P<0.001) due to their higher baseline values. Plasma vasopressin concentrations increased during trimethaphan in both groups (P<0.001); the increase was greater in the older men (62±16 versus 16±9 ng/L; P<0.05).
Vascular
-Adrenergic Sensitivity
The slope of the increase in mean BP in response to incremental phenylephrine infusion during ganglionic blockade was lower in the older men (2.1±0.3) compared with the young men (3.2±0.3 mm Hg · nL-1 · mL-1; P<0.01; Figure 3A).
|
Physiological Correlates of ANS Support of BP
The decrease in mean BP from baseline during trimethaphan was significantly related to baseline plasma norepinephrine concentration (r=0.58, P<0.001; Figure 4); the change in plasma norepinephrine with trimethaphan (r=0.67, P<0.001; Figure 4); baseline HRVSD R-R interval (r=-0.40, P<0.01); the slope of the increase in mean BP in response to phenylephrine infusion (r=0.57, P<0.001; Figure 3B); and baseline mean BP (r=0.34, P<0.05) in all subjects; and to baseline MSNA (r=0.63, P<0.005; Figure 4) in 22 subjects.
|
| Discussion |
|---|
|
|
|---|
-adrenergic vascular sensitivity seem to be important physiological correlates of ANS support of BP among young and older healthy men. Thus, our results demonstrate that changes in the ANS with healthy adult aging have a functionally significant effect on tonic BP maintenance in humans. Our findings also provide insight into some of the mechanisms involved.
ANS Support of BP with Healthy Aging
To our knowledge, the present findings are the first to demonstrate that tonic ANS support of BP, as determined by the short-term reduction in BP with ganglionic blockade, is altered in healthy older men compared with young men. Our data indicate that the key mechanism underlying this effect is an age-associated reduction in tonic cardiac vagal suppression of heart rate and cardiac output. Specifically, the greater decrease in mean BP with ganglionic blockade in the older men was mediated solely by a lack of increase in heart rate which, along with a modest decrease in stroke volume, resulted in a slight reduction in cardiac output (compared with the increase observed in young men). In the present study, the change in heart rate with ganglionic blockade among the individual men was positively related to baseline HRV, suggesting that basal cardiac vagal tone was an important determinant of the chronotropic response to the removal of ANS input.
It might be expected that ANS support of BP would be greater in older adults due to their elevated basal SNS activity, which could produce tonically elevated peripheral vasoconstriction. Indeed, baseline SNS activity and the decrease in that activity during trimethaphan were significant correlates of the reduction in mean BP with ganglionic blockade. However, although the elevated SNS activity in the older men was an important determinant of their ANS control of BP, it did not seem to play a predominant role in the tonic support of systemic vascular resistance. Rather, our results suggest that vascular
-adrenergic desensitization with age counteracted the vasoconstrictor effects of chronically elevated peripheral SNS activity in the older men. This contention is consistent with the facts that (1) the reduction in systemic vascular resistance (increase in conductance) during ganglionic blockade was not different in the 2 groups, despite greater reductions in SNS activity in the older men, and (2) in the absence of counter-regulatory reflexes, the increase in mean BP in response to systemic infusion of phenylephrine, a nonspecific
-adrenergic agonist, was smaller in the older compared with the young men.
The difference in BP between the intact and ganglionic blocked states has been reported to be greater in healthy adults with a mean age of 60 compared with younger controls, whereas the difference in heart rate was smaller in the older subjects.14 This previous investigation differed from the present study in several ways. First, the intact and ganglionic blocked conditions were studied in separate sessions at least 4 days apart (fixed order) compared with our measurements, which were performed in the same experimental session. Second, BP was determined noninvasively using an automated monitor, as opposed to our direct intra-arterial measurements. Third, the numbers of subjects studied (n=8 per group) were much smaller than in the present study (n=16 to 23 per group). Finally and importantly, the sex distribution was markedly different in the young and older groups in this earlier study (preliminary data from our laboratory suggest that the BP reduction with ganglionic blockade may be related to sex). Thus, although selective results of this prior investigation are consistent with those reported here, we believe that the findings of the present study provide the first definitive insight into changes in ANS support of BP with healthy aging in adult humans. Our results also provide additional information on the nature of the cardiovascular and ANS mechanisms involved.
Experimental Considerations
There are several experimental considerations that should be noted. First, regarding ANS control of heart rate, one might expect higher resting heart rates in the older men due to their apparent lower cardiac vagal modulation. However, consistent with the literature, 25 supine resting heart rate was similar in our young and older men. We think that the reduction in intrinsic sinus node rate (intrinsic heart rate) with aging 25 likely explains the lack of group differences observed. Our data also do not differentiate between age-related differences in vagal input to the sinoatrial node and tissue responsiveness. As such, the age-related decline in HRV could reflect either, although recent evidence indicates that chronotropic responsiveness to vagal stimulation is not affected by age in healthy adult humans. 26 Moreover, our data do not allow us to determine a potential role of basal cardiac sympathetic tone in the support of heart rate, cardiac output, and BP. Although the change in heart rate with ganglionic blockade was also related to the low frequency and total power of HRV (data not presented), the interpretation of these measures as indicators of cardiac sympathetic modulation of heart rate is unclear. 27,28
Second, age-associated differences in humoral and local factors could have exerted some influence on the change in BP with ganglionic blockade. For example, because cardiac output increased in the young, but not in the older, subjects during ganglionic blockade, it is possible that there was a greater stimulus for flow-mediated endothelium-dependent vasodilation in the young men. In addition, there was a greater increase in plasma vasopressin in the older compared with the young subjects. In rats, the reduction in BP with trimethaphan is greater in the presence of a vasopressin receptor antagonist. 29 This raises the possibility that vasopressin partially counteracts the fall in BP and causes ANS support to be underestimated. 1,15,30,31 It is not known if trimethaphan-evoked vasopressin release similarly modulates the depressor response to ganglionic blockade in humans. However, the increase in plasma vasopressin concentration during ganglionic blockade in the present study was positively related to the corresponding reduction in mean BP (r=-0.57, P<0.01). This suggests that vasopressin release is responding to the trimethaphan-induced BP decrease, not vice versa. It also indicates that the greater decrease in BP with ganglionic blockade in the older subjects is not due to an attenuated vasopressin release (ie, less vasoactive hormone counter-regulation) compared with the young men. Therefore, any influence of these factors actually would have diminished the observed age-related difference in the BP reduction with trimethaphan by increasing the magnitude of decline in young subjects (via greater flow-mediated vasodilation) and by counteracting the decrease in older subjects (via greater vasopressin response), thus causing the increase in ANS support of BP with age to be underestimated. Accordingly, we believe that our interpretation that the greater BP reductions with trimethaphan in the older men reflect a true age-related difference in tonic ANS support with age is valid.
Finally, we can provide little mechanistic insight into the similar reductions in stroke volume with ganglionic blockade in our young and older men in the present study, despite marked differences in the heart rate responses. However, the reduced stroke volume in the ganglionic blocked compared with the intact state is associated with a similarly decreased left ventricular end-diastolic volume index in healthy men and women varying in age. 14 This suggests that similar reductions in left ventricular preload may have been responsible for the lack of difference observed in the stroke volume response to ganglionic blockade in our young and older men.
Clinical Significance
The ANS plays an important role in the pathogenesis of several cardiovascular disorders, including congestive heart failure, essential hypertension, and ventricular tachyarrhythmias. 3234 The incidence of these cardiovascular disorders increases markedly with advancing age. Moreover, we 2,6,9,10,12,19,35 and others3,4 have shown that numerous changes in ANS behavior occur with age, even in healthy humans. However, a lack of information concerning the effects of such ANS changes on cardiovascular function has made it difficult to discern the respective contributions of biological (primary) aging and disease processes to changes in circulatory physiology and pathophysiology with advancing age. The findings of the present study provide new insight into ANS-mediated effects on cardiovascular control of BP with healthy aging from which the independent effects of cardiovascular disease can be determined.
Our results also may have relevance for interactions between age and the effects of antihypertensive medications. For example, the risk of orthostatic hypotension in response to some BP-lowering drugs is augmented in the elderly and is the source of substantial morbidity. 36,37 The present data are consistent with and may provide a physiological basis for this augmented hypotensive effect in older adults.
| Conclusions |
|---|
|
|
|---|
-adrenergic desensitization. Our results provide important new insight into the effects of primary aging per se on ANS support of BP, which should be of benefit in interpreting age-associated changes due to cardiovascular disease. | Acknowledgments |
|---|
Received June 28, 2001; revision received September 7, 2001; accepted September 10, 2001.
| References |
|---|
|
|
|---|
2.
Seals D, Esler M. Human ageing and the sympathoadrenal system. J Physiol. 2000; 528: 3: 407417.
3. Dauchot P, Gravenstein JS. Effects of atropine on the electrocardiogram in different age groups. Clin Pharmacol Ther. 1971; 12: 274280.[Medline] [Order article via Infotrieve]
4.
Hellman J, Stacy R. Variation of respiratory sinus arrhythmia with age. J Appl Physiol. 1976; 41: 734738.
5. Davy KP, DeSouza CA, Jones PP, et al. Elevated heart rate variability in physically active young and older adult women. Clin Sci. 1998; 94: 579584.[Medline] [Order article via Infotrieve]
6.
Taylor JA, Hayano J, Seals DR. Lesser vagal withdrawal during isometric exercise with age. J Appl Physiol. 1995; 79: 805811.
7.
Goldstein DS, Lake CR, Chernow B, et al. Age-dependence of hypertensive-normotensive differences in plasma norepinephrine. Hypertension. 1983; 5: 100104.
8.
Morrow LA. Age differences in the plasma clearance mechanisms for epinephrine and norepinephrine in humans. J Clin Endocrinol Metab. 1987; 65: 508511.
9.
Esler MD, Turner AG, Kaye DM, et al. Aging effects on human sympathetic neuronal function. Am J Physiol. 1995; 268: R278R285.
10.
Ng AV, Callister R, Johnson DG, et al. Age and gender influence muscle sympathetic nerve activity at rest in healthy humans. Hypertension. 1993; 21: 498503.
11.
Sundlof G, Wallin BG. Human muscle nerve sympathetic activity at rest. Relationship to blood pressure and age. J Physiol. 1978; 274: 621637.
12.
Davy KP, Seals DR, Tanaka H. Augmented cardiopulmonary and integrative sympathetic baroreflexes but attenuated peripheral vasoconstriction with age. Hypertension. 1998; 32: 298304.
13.
Hogikyan R, Supiano M. Arterial a-adrenergic responsiveness is decreased and SNS activity is increased in older humans. Am J Physiol. 1994; 266: E717E724.
14. White M, Leenen FHH. Aging and cardiovascular responsiveness to ß-agonist in humans: role of changes in ß-receptor responses versus baroreflex activity. Clin Pharmacol Ther. 1994; 56: 543553.[Medline] [Order article via Infotrieve]
15.
Jordan J, Toka H, Heusser K, et al. Severely impaired baroreflex-buffering in patients with monogenic hypertension and neurovascular contact. Circulation. 2000; 102: 26112618.
16.
Shannon J, Jordan J, Diedrich A, et al. Sympathetically mediated hypertension in autonomic failure. Circulation. 2000; 101: 27102715.
17.
Greenleaf JE, Convertino VA, Mangseth GR. Plasma volume during stress in man: osmolality and red cell volume. J Appl Physiol. 1979; 47: 10311038.
18.
Jones PP, Davy KP, DeSouza CA, et al. Absence of age-related decline in total blood volume in physically active females. Am J Physiol. 1997; 272: H2534H2540.
19.
Davy K, Miniclier NL, Andrews JA, et al. Elevated heart rate variability in physically active postmenopausal women: a cardioprotective effect? Am J Physiol. 1996; 271: H455H460.
20. Chandraratna P, Nanna M, McKay C, et al. Determination of cardiac output by transcutaneous continuous-wave ultrasonic Doppler computer. Am J Cardiol. 1984; 53: 234237.[Medline] [Order article via Infotrieve]
21.
Huntsman L, Stewart D, Barnes S, et al. Noninvasive Doppler determination of cardiac output in man: clinical validation. Circulation. 1983; 67: 593602.
22. Peuler JD, Johnson GA. Simultaneous single isotope radioenzyme assay of plasma norepinephrine, epinephrine, and dopamine. Life Sci. 1977; 21: 625636.[Medline] [Order article via Infotrieve]
23. Robertson G, Mahr E, Athar S, et al. The development and clinical application of a new method for the radioimmuoassay of arginine vasopressin in human plasma. J Clin Invest. 1973; 52: 23402352.
24. Wallin BG, Fagius J. Peripheral sympathetic neural activity in conscious humans. Ann Rev Physiol. 1988; 50: 565576.[Medline] [Order article via Infotrieve]
25. Lakatta EG. Aging: cardiovascular system.In: Masoro EJ, ed. Handbook of Physiology. New York: Oxford University Press; 1995: 413474.
26. OMahony D, Bennett C, Green A, et al. Reduced baroreflex sensitivity in elderly humans is not due to efferent autonomic dysfunction. Clin Sci. 2000; 98: 103110.[Medline] [Order article via Infotrieve]
27.
Eckberg D. Sympathovagal balance: a critical appraisal. Circulation. 1997; 96: 32243232.
28.
Kingwell B, Thompson J, Kaye D, et al. Heart rate spectral analysis, cardiac norepinephrine spillover, and muscle sympathetic nerve activity during human sympathetic nervous activation and failure. Circulation. 1994; 90: 234240.
29. Santajuliana D, Hornfeldt B, Osborn J. Use of ganglionic blockers to assess neurogenic pressor activity in conscious rats. J Pharmacol Toxicol Methods. 1996; 35: 4554.[Medline] [Order article via Infotrieve]
30. Baylis P, Robertson G. Osmotic and non-osmotic stimulation of vasopressin release. J Endocrinol. 1979; 83: 39P40P.
31.
Jordan J, Tank J, Diedrich A, et al. Vasopressin and blood pressure in humans. Hypertension. 2000; 36: e3e36.
32.
Dekker J, Crow R, Folsom A, et al. Low heart rate variability in a 2-minute rhythm strip predicts risk of coronary heart disease and mortality from several causes: the ARIC study. Circulation. 2000; 102: 12391244.
33.
Leimbach W, Wallin B, Victor R, et al. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation. 1986; 73: 913919.
34.
Yamada Y, Miyajima E, Tochikubo O, et al. Age-related changes in muscle sympathetic nerve activity in essential hypertension. Hypertension. 1989; 13: 870877.
35. Davy KP, Johnson D, Seals DR. Cardiovascular, plasma norepinephrine, and thermal adjustments to prolonged exercise in young and older healthy humans. Clin Physiol. 1995; 15: 169181.[Medline] [Order article via Infotrieve]
36. Chobanian A. Treatment of the elderly hypertensive patient. Am J Med. 1984; 2227.
37.
Tjoa H, Kaplan N. Treatment of hypertension in the elderly. JAMA. 1990; 264: 10151018.
This article has been cited by other articles:
![]() |
E. C. Hart, M. J. Joyner, B. G. Wallin, C. P. Johnson, T. B. Curry, J. H. Eisenach, and N. Charkoudian Age-Related Differences in the Sympathetic-Hemodynamic Balance in Men Hypertension, July 1, 2009; 54(1): 127 - 133. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. Hart, N. Charkoudian, B. G. Wallin, T. B. Curry, J. H. Eisenach, and M. J. Joyner Sex Differences in Sympathetic Neural-Hemodynamic Balance: Implications for Human Blood Pressure Regulation Hypertension, March 1, 2009; 53(3): 571 - 576. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D. Christou and D. R. Seals Decreased maximal heart rate with aging is related to reduced {beta}-adrenergic responsiveness but is largely explained by a reduction in intrinsic heart rate J Appl Physiol, July 1, 2008; 105(1): 24 - 29. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Joyner, N. Charkoudian, and B. G. Wallin A sympathetic view of the sympathetic nervous system and human blood pressure regulation Exp Physiol, June 1, 2008; 93(6): 715 - 724. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. D. Monahan Effect of aging on baroreflex function in humans Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R3 - R12. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Shibao, A. Gamboa, A. Diedrich, A. C. Ertl, K. Y. Chen, D. W. Byrne, G. Farley, S. Y. Paranjape, S. N. Davis, and I. Biaggioni Autonomic Contribution to Blood Pressure and Metabolism in Obesity Hypertension, January 1, 2007; 49(1): 27 - 33. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Masuki, J. H. Eisenach, F. A. Dinenno, and M. J. Joyner Reduced forearm {alpha}1-adrenergic vasoconstriction is associated with enhanced heart rate fluctuations in humans J Appl Physiol, March 1, 2006; 100(3): 792 - 799. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D. Christou, P. P. Jones, J. Jordan, A. Diedrich, D. Robertson, and D. R. Seals Women Have Lower Tonic Autonomic Support of Arterial Blood Pressure and Less Effective Baroreflex Buffering Than Men Circulation, February 1, 2005; 111(4): 494 - 498. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Seals and F. A. Dinenno Collateral damage: cardiovascular consequences of chronic sympathetic activation with human aging Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H1895 - H1905. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D. Christou, P. Parker Jones, A. E. Pimentel, and D. R. Seals Increased abdominal-to-peripheral fat distribution contributes to altered autonomic-circulatory control with human aging Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1530 - H1537. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tank, J. Jordan, A. Diedrich, M. Obst, R. Plehm, F. C. Luft, and V. Gross Clonidine Improves Spontaneous Baroreflex Sensitivity in Conscious Mice Through Parasympathetic Activation Hypertension, May 1, 2004; 43(5): 1042 - 1047. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Stratton, W. C. Levy, J. H. Caldwell, A. Jacobson, J. May, D. Matsuoka, and K. Madden Effects of aging on cardiovascular responses to parasympathetic withdrawal J. Am. Coll. Cardiol., June 4, 2003; 41(11): 2077 - 2083. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D. Christou, P. P. Jones, and D. R. Seals Baroreflex Buffering in Sedentary and Endurance Exercise-Trained Healthy Men Hypertension, June 1, 2003; 41(6): 1219 - 1222. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. P. Jones, D. D. Christou, J. Jordan, and D. R. Seals Baroreflex Buffering Is Reduced With Age in Healthy Men Circulation, April 8, 2003; 107(13): 1770 - 1774. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. P. Jones, L. F Shapiro, G. A Keisling, R. A Quaife, and D. R Seals Is autonomic support of arterial blood pressure related to habitual exercise status in healthy men? J. Physiol., April 15, 2002; 540(2): 701 - 706. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. P. Jones, L. F. Shapiro, G. A. Keisling, R. A. Quaife, and D. R. Seals Is autonomic support of arterial blood pressure related to habitual exercise status in healthy men? J. Physiol., February 15, 2002; (2002) 200101366. [Abstract] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |